Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation (UPSAT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04344561|
Recruitment Status : Recruiting
First Posted : April 14, 2020
Last Update Posted : June 24, 2020
COVID-19 is a respiratory illness caused by SARS-CoV-2 with a range of symptoms from mild, self-limiting respiratory tract infections to severe progressive pneumonia, multiorgan dysfunction and death. A portion of individuals with COVID-19 experience life-threatening hypoxia requiring supplemental oxygen and mechanical ventilation. Management of hypoxia in this population is complicated by contraindication of non-invasive ventilation and limitations in access to mechanical ventilation and critical care staff given the clinical burden of disease. Positional therapy is readily deployable and may ultimately be used to treat COVID-19 related respiratory failure in resources limited settings; and, it has been demonstrated to improve oxygenation and is easy to implement in the clinical setting.
The overall goal of this randomized controlled trial is to establish the feasibility of performing a randomized trial using a simple, minimally invasive positional therapy approach to improve hypoxia and reduce progression to mechanical ventilation. The objectives are to examine the effectiveness and feasibility of maintaining an inclined position in patients with confirmed or suspected COVID-19 associated hypoxemic respiratory failure. The investigators hypothesize that (1) oxyhemoglobin saturation will improve with therapy, (2) participants will tolerate and adhere to the intervention, and that (3) participants who adhere to positional therapy will have reduced rates of mechanical ventilation at 72 hours. If successful, this feasibility trial will demonstrate that a simple, readily deployed nocturnal postural maneuver is well tolerated and reverses underlying defects in ventilation and oxygenation due to COVID-19. It will also inform the design of a pivotal Phase III trial with estimates of sample sizes for clinically relevant outcomes.
|Condition or disease||Intervention/treatment||Phase|
|COVID Hypoxic Respiratory Failure||Other: Postural Positioning||Not Applicable|
Study Design: The investigators will conduct a pilot study to examine the acute effects of inclined posture on oxyhemoglobin saturation and the feasibility of conducting randomized controlled clinical trial among patients with confirmed or suspected COVID-19-associated hypoxia.
In a subgroup of participants, the investigators will examine the acute effect of postural therapy (15-degree incline on hospital beds) on oxyhemoglobin saturation among hypoxic patients to establish a biologic response. The investigators will enroll a subset of participants (n=16) who will lie supine on hospital beds, which will be placed in the horizontal (flat) or 15-degree inclined (reverse Trendelenberg) orientation in random order. During this time, the investigators will continuous record pulse oximetry, pulse rate and variations in peripheral arterial tone with WatchPAT one devices. Subjects will be visually monitored for work of breathing during this time. If work of breathing becomes excessive, as defined as a sustain respiratory rate of >25 and an increase of >5 breaths per minute from baseline, or oxygenation decreases below 88% for > 30 seconds in the inclined position, then maneuvers will be stopped. If the patient meets these criteria in the flat position, then the investigators sit the patient upright, and allow breathing to return to baseline before examining responses in the inclined position.
The investigators will randomize participants to have beds placed in 15-degree incline or usual care (ad-lib positioning) for 72 hours. During the first night in a subgroup of participants, the investigators will record oxygenation, sleep wake state and markers of sympathetic activity with WatchPAT One devices, which can obtain cardiopulmonary parameters with high temporal resolution. The investigators will obtain vital signs from the data warehouse, which archives telemetry data with a maximum sampling frequency of 1 minute. The investigators will record adherence with continuous accelerometry sensors placed on the bed rails and on the anterolateral surface of participants' chests to measure bed and participants' positions, respectively. Aside from position, participants will receive usual treatment for COVID-19.
The investigators will enroll in 3 phases. At the end of each phase, the investigators will assess for completion of milestones for proceeding to the subsequent phase, as detailed below:
- Pilot Study: The investigators will pilot the study in 16 participants to obtain critical information on logistics of conducting the trial including performance of recording instruments in a biocontainment environment, to examine the feasibility of the intervention, perform preliminary safety evaluations to ascertain potential harm and to determine whether the intervention results in a meaningful difference in body position.
- Phase II RCT: If inclined therapy results in a difference in body position and no significant safety issues were detected, the investigators will conduct a phase II randomized-controlled trial (RCT) in 70 participants (see sample size calculation below) to estimate the effect size of inclined position on rates of intubation and determine sample size for a Phase III trial.
Randomization will be occur in both phases and will be stratified by study phase and study site.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT)|
|Actual Study Start Date :||May 25, 2020|
|Estimated Primary Completion Date :||May 1, 2021|
|Estimated Study Completion Date :||May 1, 2021|
Experimental: Postural Positioning
Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
Other: Postural Positioning
Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
No Intervention: Standard Care
Participants in this group will have beds managed per standard nursing protocol.
- Incidence of Mechanical Ventilation [ Time Frame: 72 hours ]Number of participants needing mechanical ventilation over total number of participants per arm.
- Number of participants with supplemental oxygen requirements [ Time Frame: 72 hours ]Number of participants with supplemental oxygen requirements.
- Mean oxyhemoglobin saturation [ Time Frame: At 24, 48 and 72 hours ]Mean oxyhemoglobin saturation (percentage) measured over a 24-hour period.
- Mean Nocturnal Oxyhemoglobin Saturation [ Time Frame: Measured between 10pm and 6am daily, up to 72 hours ]Mean oxyhemoglobin saturation (percentage) measured over an 8-hour period (between 10pm and 6am).
- Heart Rate [ Time Frame: At 10, 24, 48 and 72 hours ]Heart Rate (beats per minute) on Routine Vital Sign Assessment.
- Respiratory Rate [ Time Frame: At 10, 24, 48 and 72 hours ]Respiratory Rate (cycles per minute) on Routine Vital Sign Assessment.
- Percentage of time in the assigned position [ Time Frame: 72 hours ]Percentage of time participants stay in the assigned position will be used to determine adherence.
- Acute change in oxyhemoglobin saturation [ Time Frame: During the final 7 minutes at each position, up to 72 hours ]Mean oxyhemoglobin saturation (percentage) during final 7 minutes in a position.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04344561
|Contact: Luu Pham, MDfirstname.lastname@example.org|
|Contact: Trishul Siddharthan, MDemail@example.com|
|United States, Maryland|
|Johns Hopkins Bayview Hospital||Recruiting|
|Baltimore, Maryland, United States, 21224|
|Contact: Luu Pham, MD 410-550-2118 firstname.lastname@example.org|
|Johns Hopkins Hospital||Recruiting|
|Baltimore, Maryland, United States, 21287|
|Contact: Trishul Siddharthan, MD email@example.com|
|Principal Investigator:||Luu Pham, MD||Johns Hopkins University|